Addiction Treatment Market - 2026-2035

June 2026 | 45 pages | ID: AD55FE57EEB0EN
DataM Intelligence

Abstracts

Addiction Treatment Market reached US$ 12.45 Billion in 2025 and is expected to reach US$ 23.9 billion by 2035, growing with a CAGR of 6.70% during the forecast period 2026-2035.

The Addiction Treatment Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.

A Addiction Treatment Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.

By Addiction Type

• Alcohol Use Disorder*
• Opioid Use Disorder
• Heroin Addiction
• Prescription Opioid Addiction
• Synthetic Opioid Addiction
• Nicotine and Tobacco Addiction
• Cigarette Addiction
• Smokeless Tobacco Addiction
• Vaping and E-Cigarette Addiction
• Cannabis Use Disorder
• Stimulant Use Disorder
• Cocaine Addiction
• Methamphetamine Addiction
• Prescription Stimulant Addiction
• Prescription Drug Addiction
• Benzodiazepine Addiction
• Sedative and Hypnotic Addiction
• Prescription Painkiller Addiction
• Behavioral Addiction
• Gambling Addiction
• Gaming Addiction
• Internet and Digital Addiction
• Polysubstance Use Disorder
• Others

By Treatment Modality

• Medication-Assisted Treatment*
• Opioid Dependence Treatment
• Alcohol Dependence Treatment
• Nicotine Dependence Treatment
• Detoxification and Withdrawal Management
• Behavioral Therapy and Counseling
• Cognitive Behavioral Therapy
• Motivational Interviewing
• Contingency Management
• Residential Rehabilitation
• Outpatient Rehabilitation
• Harm Reduction Programs
• Digital Therapeutics and Telehealth
• Recovery Management and Aftercare

By Medication Class

• Opioid Agonists*
• Methadone
• Opioid Partial Agonists
• Buprenorphine
• Buprenorphine and Naloxone Combination Products
• Opioid Antagonists
• Naltrexone
• Naloxone
• Alcohol Dependence Medications
• Disulfiram
• Acamprosate
• Nicotine Replacement Therapies
• Nicotine Patches
• Nicotine Gums
• Nicotine Lozenges
• Nicotine Inhalers
• Nicotine Nasal Sprays
• Smoking Cessation Drugs
• Varenicline
• Bupropion
• Adjunctive Psychiatric Medications
• Antidepressants
• Anxiolytics
• Antipsychotics
• Mood Stabilizers

By Care Delivery Setting

• Hospitals*
• Hospitals
• Specialty Addiction Treatment Centers
• Residential Rehabilitation Centers
• Outpatient Clinics
• Community Health Centers
• Digital Care Platforms
• Correctional Facilities

By Distribution Channel

• Hospital Pharmacies*
• Retail Pharmacies
• Online Pharmacies
• Public Health and Government Supply Channels

By End User

• Individual Patients*
• Healthcare Providers
• Government and Public Health Agencies
• Employers and Workplace Wellness Programs
• Correctional Health Programs
• Community-Based Organizations

Regional Analysis for Addiction Treatment Market:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

This Report Covers:

• Go-to-market Strategy.
• Neutral perspective on the market performance.
• Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
• Customized regional/country reports as per request and country level analysis.
• Potential & niche segments and regions exhibiting promising growth covered.
• Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Research Process:

Both primary and secondary data sources have been used in the global Addiction Treatment Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Contents

1. METHODOLOGY AND SCOPE

1.1. Research Data
  1.1.1. Secondary Data
  1.1.2. Primary Data
  1.1.3. CAGR Analysis
1.2. Market Size Estimation Methodology
  1.2.1. Bottom-Up Approach
  1.2.2. Top-Down Approach
1.3. Market Breakdown & Data Triangulation
1.4. Research Assumptions
1.5. Limitations

2. DEFINITION AND OVERVIEW

2.1. Study Objectives
2.2. Market Definition
2.3. Market Scope
2.4. Stakeholder Analysis
2.5. Currency Considered
2.6. Study Period

3. EXECUTIVE SUMMARY

3.1. Key Takeaways
3.2. Top To Bottom Analysis
3.3. Market Share Analysis
3.4. Data Points from Key Primary Interviews
3.5. Data Points from Key Secondary Databases
3.6. Market Snapshot
3.7. Geographical Snapshot

4. DYNAMICS

4.1. Impacting Factors
  4.1.1. Drivers
    4.1.1.1. Rising burden of alcohol use disorder, opioid use disorder, nicotine dependence and polysubstance abuse is increasing the need for structured treatment pathways.
    4.1.1.2. Growing adoption of medication-assisted treatment is improving clinical outcomes by reducing withdrawal symptoms, cravings and relapse risk.
    4.1.1.3. Increasing opioid overdose incidents are accelerating demand for naloxone, harm reduction programs and emergency overdose reversal solutions.
  4.1.2. Restraints
    4.1.2.1. Social stigma and low treatment-seeking behavior continue to reduce early diagnosis and patient enrollment.
    4.1.2.2. Shortage of trained addiction specialists, counselors and behavioral health professionals limits treatment capacity.
  4.1.3. Impact Analysis—Drivers and Restraints
  4.1.4. Opportunity
    4.1.4.1. Integrated recovery models combining medication, behavioral therapy, digital monitoring and aftercare offer strong commercial potential.
    4.1.4.2. Long-acting formulations and abuse-deterrent therapies create opportunities for pharma companies to improve adherence and reduce misuse risk.
  4.1.5. Trends
    4.1.5.1. The market is shifting from short-term detoxification to long-term recovery management and relapse prevention.
    4.1.5.2. Medication-assisted treatment is becoming a core standard of care for opioid and alcohol dependence.
  4.1.6. Challenges

5. INDUSTRY ANALYSIS

5.1. Porter’s Five Force Analysis
5.2. Political Factors
5.3. Social Factors
  5.3.1. Rising substance use disorder burden is increasing the need for structured addiction treatment programs
  5.3.2. Growing awareness around mental health and behavioral health is improving treatment-seeking behavior
  5.3.3. Increasing social focus on opioid overdose prevention and relapse management is supporting adoption of medication-assisted treatment and harm reduction programs
5.4. Economic Factors
  5.4.1. Rising healthcare costs linked to overdose, hospitalization and relapse are driving investment in evidence-based addiction treatment solutions
  5.4.2. Expansion of public health funding, insurance coverage and government-supported substance use programs is creating recurring demand for addiction treatment providers
  5.4.3. Growing employer spending on mental health, workplace wellness and substance abuse management is strengthening commercial growth across the Addiction Treatment Market
5.5. Geopolitical Factors
5.6. Supply/Value Chain Analysis
5.7. Pricing Analysis
5.8. Regulatory Analysis
5.9. Technology Landscape
5.10. Innovation & R&D Trends
5.11. Sustainability and ESG Analysis
5.12. Risk Avoidance Model
5.13. Go-To-Market (GTM) Strategy
5.14. BCG Matrix
5.15. Business Models Analysis
5.16. Demand-Supply Gap
5.17. Risk Mitigation Framework
5.18. Compliance Roadmap
5.19. Strategic Implications
5.20. Emerging Opportunities
5.21. Adoption Trends
5.22. Disruption Analysis
5.23. DMI Opinion

6. BY ADDICTION TYPE

6.1. Introduction
  6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Addiction Type
  6.1.2. Market Attractiveness Index, By Addiction Type
6.2. Alcohol Use Disorder*
  6.2.1. Introduction
  6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Opioid Use Disorder
  6.3.1. Heroin Addiction
  6.3.2. Prescription Opioid Addiction
  6.3.3. Synthetic Opioid Addiction
6.4. Nicotine and Tobacco Addiction
  6.4.1. Cigarette Addiction
  6.4.2. Smokeless Tobacco Addiction
  6.4.3. Vaping and E-Cigarette Addiction
6.5. Cannabis Use Disorder
6.6. Stimulant Use Disorder
  6.6.1. Cocaine Addiction
  6.6.2. Methamphetamine Addiction
  6.6.3. Prescription Stimulant Addiction
6.7. Prescription Drug Addiction
  6.7.1. Benzodiazepine Addiction
  6.7.2. Sedative and Hypnotic Addiction
  6.7.3. Prescription Painkiller Addiction
6.8. Behavioral Addiction
  6.8.1. Gambling Addiction
  6.8.2. Gaming Addiction
  6.8.3. Internet and Digital Addiction
6.9. Polysubstance Use Disorder
6.10. Others

7. BY TREATMENT MODALITY

7.1. Introduction
  7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Modality
  7.1.2. Market Attractiveness Index, By Treatment Modality
7.2. Medication-Assisted Treatment*
  7.2.1. Introduction
  7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  7.2.3. Opioid Dependence Treatment
  7.2.4. Alcohol Dependence Treatment
  7.2.5. Nicotine Dependence Treatment
7.3. Detoxification and Withdrawal Management
7.4. Behavioral Therapy and Counseling
  7.4.1. Cognitive Behavioral Therapy
  7.4.2. Motivational Interviewing
  7.4.3. Contingency Management
7.5. Residential Rehabilitation
7.6. Outpatient Rehabilitation
7.7. Harm Reduction Programs
7.8. Digital Therapeutics and Telehealth
7.9. Recovery Management and Aftercare

8. BY MEDICATION CLASS

8.1. Introduction
  8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Class
  8.1.2. Market Attractiveness Index, By Medication Class
8.2. Opioid Agonists*
  8.2.1. Introduction
  8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  8.2.3. Methadone
8.3. Opioid Partial Agonists
  8.3.1. Buprenorphine
  8.3.2. Buprenorphine and Naloxone Combination Products
8.4. Opioid Antagonists
  8.4.1. Naltrexone
  8.4.2. Naloxone
8.5. Alcohol Dependence Medications
  8.5.1. Disulfiram
  8.5.2. Acamprosate
  8.5.3. Naltrexone
8.6. Nicotine Replacement Therapies
  8.6.1. Nicotine Patches
  8.6.2. Nicotine Gums
  8.6.3. Nicotine Lozenges
  8.6.4. Nicotine Inhalers
  8.6.5. Nicotine Nasal Sprays
8.7. Smoking Cessation Drugs
  8.7.1. Varenicline
  8.7.2. Bupropion
8.8. Adjunctive Psychiatric Medications
  8.8.1. Antidepressants
  8.8.2. Anxiolytics
  8.8.3. Antipsychotics
  8.8.4. Mood Stabilizers

9. BY CARE DELIVERY SETTING

9.1. Introduction
  9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Care Delivery Setting
  9.1.2. Market Attractiveness Index, By Care Delivery Setting
9.2. Hospitals*
  9.2.1. Introduction
  9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Hospitals
9.4. Specialty Addiction Treatment Centers
9.5. Residential Rehabilitation Centers
9.6. Outpatient Clinics
9.7. Community Health Centers
9.8. Digital Care Platforms
9.9. Correctional Facilities

10. BY DISTRIBUTION CHANNEL

10.1. Introduction
  10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospital Pharmacies*
  10.2.1. Introduction
  10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Retail Pharmacies
10.4. Online Pharmacies
10.5. Public Health and Government Supply Channels

11. BY END USER

11.1. Introduction
  11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  11.1.2. Market Attractiveness Index, By End User
11.2. Individual Patients*
  11.2.1. Introduction
  11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Healthcare Providers
11.4. Government and Public Health Agencies
11.5. Employers and Workplace Wellness Programs
11.6. Correctional Health Programs
11.7. Community-Based Organizations

12. BY REGION

12.1. Introduction
  12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  12.1.2. Market Attractiveness Index, By Region
12.2. North America*
  12.2.1. Introduction
  12.2.2. Key Region-Specific Dynamics
  12.2.3. Market Size Analysis and Y-o-Y Growth Analysis, By Addiction Type
  12.2.4. Market Size Analysis and Y-o-Y Growth Analysis, By Treatment Modality
  12.2.5. Market Size Analysis and Y-o-Y Growth Analysis, By Medication Class
  12.2.6. Market Size Analysis and Y-o-Y Growth Analysis, By Care Delivery Setting
  12.2.7. Market Size Analysis and Y-o-Y Growth Analysis, By Distribution Channel
  12.2.8. Market Size Analysis and Y-o-Y Growth Analysis, By End User

13. MARKET SIZE ANALYSIS AND Y-O-Y GROWTH ANALYSIS (%), BY COUNTRY

13.1. U.S.
  13.1.1. Canada
    13.1.1.1. Mexico
13.2. Europe
  13.2.1. Introduction
  13.2.2. Key Region-Specific Dynamics
  13.2.3. Market Size Analysis and Y-o-Y Growth Analysis, By Addiction Type
  13.2.4. Market Size Analysis and Y-o-Y Growth Analysis, By Treatment Modality
  13.2.5. Market Size Analysis and Y-o-Y Growth Analysis, By Medication Class
  13.2.6. Market Size Analysis and Y-o-Y Growth Analysis, By Care Delivery Setting
  13.2.7. Market Size Analysis and Y-o-Y Growth Analysis, By Distribution Channel
  13.2.8. Market Size Analysis and Y-o-Y Growth Analysis, By End User
  13.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    13.2.9.1. Germany
    13.2.9.2. UK
    13.2.9.3. France
    13.2.9.4. Russia
    13.2.9.5. Spain
    13.2.9.6. Italy
    13.2.9.7. Poland
    13.2.9.8. Rest of Europe
13.3. Latin America
  13.3.1. Introduction
  13.3.2. Key Region-Specific Dynamics
  13.3.3. Market Size Analysis and Y-o-Y Growth Analysis, By Addiction Type
  13.3.4. Market Size Analysis and Y-o-Y Growth Analysis, By Treatment Modality
  13.3.5. Market Size Analysis and Y-o-Y Growth Analysis, By Medication Class
  13.3.6. Market Size Analysis and Y-o-Y Growth Analysis, By Care Delivery Setting
  13.3.7. Market Size Analysis and Y-o-Y Growth Analysis, By Distribution Channel
  13.3.8. Market Size Analysis and Y-o-Y Growth Analysis, By End User
  13.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    13.3.9.1. Brazil
    13.3.9.2. Argentina
    13.3.9.3. Rest of Latin America
13.4. Asia-Pacific
  13.4.1. Introduction
  13.4.2. Key Region-Specific Dynamics
  13.4.3. Market Size Analysis and Y-o-Y Growth Analysis, By Addiction Type
  13.4.4. Market Size Analysis and Y-o-Y Growth Analysis, By Treatment Modality
  13.4.5. Market Size Analysis and Y-o-Y Growth Analysis, By Medication Class
  13.4.6. Market Size Analysis and Y-o-Y Growth Analysis, By Care Delivery Setting
  13.4.7. Market Size Analysis and Y-o-Y Growth Analysis, By Distribution Channel
  13.4.8. Market Size Analysis and Y-o-Y Growth Analysis, By End User
  13.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    13.4.9.1. China
    13.4.9.2. India
    13.4.9.3. Japan
    13.4.9.4. Australia
    13.4.9.5. South Korea
    13.4.9.6. Indonesia
    13.4.9.7. Malaysia
    13.4.9.8. Rest of Asia-Pacific
13.5. Middle East and Africa
  13.5.1. Introduction
  13.5.2. Key Region-Specific Dynamics
  13.5.3. Market Size Analysis and Y-o-Y Growth Analysis, By Addiction Type
  13.5.4. Market Size Analysis and Y-o-Y Growth Analysis, By Treatment Modality
  13.5.5. Market Size Analysis and Y-o-Y Growth Analysis, By Medication Class
  13.5.6. Market Size Analysis and Y-o-Y Growth Analysis, By Care Delivery Setting
  13.5.7. Market Size Analysis and Y-o-Y Growth Analysis, By Distribution Channel
  13.5.8. Market Size Analysis and Y-o-Y Growth Analysis, By End User
  13.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    13.5.9.1. UAE
    13.5.9.2. Saudi Arabia
    13.5.9.3. South Africa
    13.5.9.4. Israel
    13.5.9.5. Turkiye
    13.5.9.6. Rest of Middle East and Africa

14. COMPETITIVE LANDSCAPE

14.1. Competitive Scenario
14.2. Market Share Analysis - Global
14.3. Market Share Analysis - North America
14.4. Market Share Analysis - Europe
14.5. Market Share Analysis - Asia-Pacific
14.6. Mergers and Acquisitions Analysis
14.7. Partner Identification Analysis
14.8. Investment & Funding Landscape
14.9. Strategic Alliances & Innovation Pipeline

15. COMPANY PROFILES

15.1. Indivior Inc.*
  15.1.1. Company Overview
  15.1.2. Product Portfolio and Description
  15.1.3. Revenue Analysis
  15.1.4. Pricing Analysis
  15.1.5. SWOT Analysis
  15.1.6. Recent Developments
    15.1.6.1. Major Deals
    15.1.6.2. M&A
    15.1.6.3. Collaboration
    15.1.6.4. Acquisition
    15.1.6.5. Joint Ventures
    15.1.6.6. Innovations
  15.1.7. Recent News
    15.1.7.1. Events
    15.1.7.2. Conferences
    15.1.7.3. Symposiums
    15.1.7.4. Webinars
15.2. Alkermes plc
15.3. Camurus AB
15.4. Braeburn Inc.
15.5. Orexo AB
15.6. Teva Pharmaceutical Industries Ltd.
15.7. Viatris Inc.
15.8. Hikma Pharmaceuticals PLC
15.9. Emergent BioSolutions Inc.
15.10. Kenvue Inc.
15.11. Dr. Reddy’s Laboratories Ltd.
15.12. Perrigo Company plc
15.13. Cipla Ltd.
15.14. Acadia Healthcare Company Inc.
15.15. BayMark Health Services (LIST NOT EXHAUSTIVE)

16. APPENDIX

16.1. About Us and Services
16.2. Contact Us